RxDoctor Payments Data

Piti Ratanapanichkich, MD

Nephrology · Troy, MINPI 1336110592

Payments from drug & device makers

$1,002in general payments, 2019–2025

Across 12 payments — averaging $83.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$344
  • Otsuka America Pharmaceutical, Inc.$161
  • Nxstage Medical, Inc.$153
  • Recor Medical Inc$125
  • Mallinckrodt Hospital Products Inc.$109
  • Ablative Solutions, Inc.$87
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$1,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)3$344
Otsuka America Pharmaceutical, Inc.3$161
Nxstage Medical, Inc.2$153
Recor Medical Inc1$125
Mallinckrodt Hospital Products Inc.1$109
Ablative Solutions, Inc.1$87
Ardelyx, Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,002 in reported general payments places this provider in the 50th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$247,656
Medicare patients
561
Services billed
2,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol110$75,454
KerendiaFinerenone31$26,728
JardianceEmpagliflozin14$10,529
Sevelamer Carbonate17$7,351
Calcitriol231$6,062
Losartan Potassium172$2,226
Metoprolol Succinate77$1,604
Potassium Citrate ErPotassium Citrate12$650
Furosemide97$583
Amlodipine Besylate81$548
Potassium Chloride19$498
Doxazosin Mesylate19$495
Vitamin D2Ergocalciferol (Vitamin D2)30$417
Allopurinol44$397
Atorvastatin Calcium21$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$344$75,454110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 325 nephrology providers in Michigan.

Other nephrology in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →